The Hong Kong product approval for Bactiguard’s central venous catheters for infection prevention has been announced by the Medical Device Control Office. Hong Kong is a small, but strategically important market, as it serves as a reference for new approvals and market acceptance in neighbouring China.
The Medical Device Control Office in Hong Kong, has announced the regulatory approval of Bactiguard’s central venous catheters for infection prevention (BIP CVC). The approval was confirmed much earlier than expected. This means Bactiguard can start marketing activities 8-9 months earlier than planned.
Bactiguard has earlier received Hong Kong product approval for its infection preventive urinary catheters (BIP Foley) and sales in started in 2016. With the new product approval, we can provide a more comprehensive range of products for effective infection prevention to the hospitals in Hong Kong.
There is an increasing focus on preventing catheter-related infections, especially in ICUs and cancer care, where most of the patients are infection-prone and CVCs are frequently used in their treatment.
Catheter related bloodstream infections (CBRSI), also known as Central Line Associated Bloodstream Infections (CLABSI), account for a large proportion of healthcare associated infections (HAI) in patients using medical devices, such as central venous catheters (CVC). These infections can lead to serious complications, causing patient suffering as well as increased mortality and healthcare costs. In addition, these infections are often treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes.
For further information, please contact:
Johan Rugfelt, COO, mobile +46 708 724 739
 Klevens RM et al, Public Health Rep. 2007 Mar-Apr;122(2):160-6